SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
ELTX reported Third Quarter 2026 results. The price and volatility reaction is pending.
ELTXearnings

Earnings reactions, page 5

Elicio Therapeutics, Inc. (ELTX) Q3 FY2026 earnings

November 6, 2026 · SharpeIQ Research Desk

Reported results

  • R&D expense for the third quarter of 2026 was $4.9 million.
  • G&A expense for the third quarter of 2026 was $3.6 million.
  • Net loss for the third quarter of 2026 was $8.0 million.
  • Net loss per share (basic and diluted) for the third quarter of 2026 was $0.30.
  • Cash and cash equivalents were $30.9 million as of September 30, 2026.

Guidance

  • The Company expects that its current cash and cash equivalents will support operations into the second quarter of 2027.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →